- KR₩96bn
- KR₩70bn
- KR₩11bn
Annual balance sheet for Cytogen, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 15,894 | 35,377 | 16,101 | 54,838 | 41,201 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,022 | 199 | 880 | 800 | 4,755 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 22,400 | 43,589 | 19,389 | 56,003 | 48,079 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,733 | 2,808 | 3,104 | 4,980 | 6,828 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 28,311 | 55,528 | 41,220 | 74,450 | 72,478 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1,164 | 6,791 | 33,930 | 10,747 | 4,715 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 9,974 | 32,519 | 35,564 | 21,095 | 23,895 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 18,337 | 23,009 | 5,656 | 53,355 | 48,583 |
Total Liabilities & Shareholders' Equity | 28,311 | 55,528 | 41,220 | 74,450 | 72,478 |
Total Common Shares Outstanding |